Dale Gray, MD
Internal Medicine · Rockford, ILNPI 1043252075
Payments from drug & device makers
Across 382 payments — averaging $16.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$596
- AbbVie$586
- Novo Nordisk$501
- Pfizer$454
- Boehringer Ingelheim$450
- Johnson & Johnson$396
- plus $3K from 31 others
What the payments were for
- Food & beverage$6,17898%
- Education$1082%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 36 | $596 |
| AbbVie(2 entities) | 36 | $586 |
| Novo Nordisk | 29 | $501 |
| Pfizer | 30 | $454 |
| Boehringer Ingelheim | 32 | $450 |
| Johnson & Johnson | 25 | $396 |
| Lilly USA, LLC | 23 | $370 |
| Merck | 18 | $300 |
| GSK | 16 | $288 |
| Sanofi-aventis U.S. LLC | 16 | $274 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $270 |
| E.r. Squibb & Sons, L.L.C. | 14 | $265 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $189 |
| Bayer | 6 | $122 |
| Adlon Therapeutics L.p. | 6 | $105 |
| Astellas Pharma US Inc | 3 | $100 |
| Novartis | 6 | $96 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $89 |
| Otsuka America Pharmaceutical, Inc. | 4 | $74 |
| Kowa Pharmaceuticals America, Inc. | 5 | $71 |
| Amgen(2 entities) | 5 | $64 |
| Dexcom, Inc. | 3 | $63 |
| Sunovion Pharmaceuticals Inc. | 6 | $61 |
| Sumitomo Pharma America, Inc. | 3 | $52 |
| Mylan Specialty L.p. | 3 | $52 |
| Eisai Inc. | 3 | $51 |
| Biohaven Pharmaceuticals, Inc. | 3 | $51 |
| Amneal Pharmaceuticals LLC | 3 | $45 |
| Genentech USA, Inc. | 3 | $42 |
| Amarin Pharma, Inc. | 2 | $42 |
| Abbott | 2 | $40 |
| Nevro Corp. | 2 | $35 |
| Impel Pharmaceuticals Inc. | 1 | $25 |
| Smith+Nephew | 1 | $19 |
| Almatica Pharma LLC | 1 | $16 |
| Shire North American Group Inc | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$6,285 in reported general payments places this provider in the 90th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 115 | $128,686 |
| JardianceEmpagliflozin | 87 | $72,102 |
| XareltoRivaroxaban | 54 | $51,954 |
| TrulicityDulaglutide | 26 | $40,680 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 26 | $33,567 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $29,140 |
| FarxigaDapagliflozin Propanediol | 30 | $28,706 |
| MounjaroTirzepatide | 26 | $27,501 |
| OzempicSemaglutide | 25 | $26,996 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 34 | $20,751 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $19,337 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $17,173 |
| MyrbetriqMirabegron | 25 | $16,147 |
| RybelsusSemaglutide | 13 | $14,436 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 28 | $8,555 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $454 | $128,686115 claims |
| Boehringer IngelheimJardiance | $450 | $72,10287 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $370 | $68,18152 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Arexvy, Shingrix | $288 | $59,694113 claims |
| Johnson & JohnsonXarelto | $396 | $51,95454 claims |
| Novo NordiskOzempic, Rybelsus | $501 | $41,43238 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $274 | $37,27138 claims |
| AstraZenecaFarxiga, Symbicort | $596 | $34,97244 claims |
| Astellas Pharma US IncMyrbetriq | $100 | $16,14725 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $270 | $6,92012 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $71 | $5,63215 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $45 | $3,643450 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Rockford
- Mary BrownRockford$16M
- Dennis LevinsonChicago$25.3M
- Andrew BartlettChampaign$4.1M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Jeffrey GeohasEvanston$2.3M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
- Yoko MomoyamaLombard$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.